Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 9, 2017
45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies SEATTLE, Nov. 09, 2017 (GLOBE NEWSWIRE) --  NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational researc...
Nov 2, 2017
SEATTLE, Nov. 02, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2017. The results were consistent with the company's announcement of preliminary revenue on October 11, 201...
Oct 26, 2017
SEATTLE and PITTSBURGH, Oct. 26, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and the NSABP Foundation, Inc. (NSABP), an academic research organization supported by the National Cancer Institute (NCI) and industry funding, today...
Oct 11, 2017
SEATTLE, Oct. 11, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced preliminary total revenue of approximately $25.9 million to $26.9 million for the third quarter, including product and service revenue of approximate...
Sep 18, 2017
SEATTLE, Sept. 18, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company has demonstrated the capability of its Hyb & Seq technology to perform liquid biopsy measurement.  The proof-of-principle work was ...
Sep 7, 2017
SEATTLE, Sept. 07, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company's presentation at the 2017 Morgan Stanley Global Healthcare Conference in New York City, on Tuesday, September 12, ...
Sep 5, 2017
SEATTLE, Sept. 05, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Anthem has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature Assay.  This positive coverage decision is i...
Aug 31, 2017
SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company's presentation at the 2017 Baird Global Healthcare Conference in New York City, on Thursday, September 7, 2017. ...
Aug 8, 2017
SEATTLE, Aug. 08, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the second quarter of 2017.  Second Quarter Financial Highlights  Total revenue of $34.6 million, 53% year-over-year growt...
Aug 8, 2017
SEATTLE and FREMONT, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and Lam Research Corporation (Nasdaq:LRCX), a global supplier of innovative wafer fabrication equipment and services to the semiconductor industr...
Jul 10, 2017
SEATTLE, July 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release second quarter 2017 financial results after the close of trading on Tuesday, August 8, 2017. Company management will ho...
Jul 5, 2017
SEATTLE, July 05, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that J. Chad Brown has been appointed Senior Vice President of Sales and Marketing, effective July 5, 2017.    Mr. Brown is a senior healthcare ...
Jun 6, 2017
SEATTLE, June 06, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock at a price of $16.75 per share, which in...
Jun 1, 2017
SEATTLE, June 01, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $16.75 per share pursuant to its existing shelf ...
May 31, 2017
SEATTLE, May 31, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an agreement to sell 2,750,000 shares of its common stock to Robert W. Baird & Co. Incorporated as the underwriter in an underwritten public offering ...
May 30, 2017
SEATTLE, May 30, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company's presentation at the 2017 Jefferies Healthcare Conference in New York City, on Wednesday, June 7, 2017. The web...
May 25, 2017
More than 35 Abstracts Demonstrate the Value of the nCounter Platform for Targeted Discovery, Biomarker Development and Diagnostic Applications in Cancer Research and Immuno-Oncology NanoString's New Digital Spatial Profiling Technology Featured in Two Abstracts SEATTLE, May 25, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ...
May 10, 2017
SEATTLE, May 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Elisha W. Finney, former executive vice president and chief financial officer at Varian Medical Systems (NYSE: VAR), to its Board o...
May 4, 2017
SEATTLE, May 04, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter of 2017. First Quarter Financial Highlights Total revenue of $18.1 million, 23% year-over-year growthTota...
Apr 5, 2017
SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2017 financial results after the close of trading on Thursday, May 4, 2017. Company management will host...
Apr 3, 2017
WASHINGTON, April 03, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted the validation of its novel Digital Spatial Profiling (DSP) technology by the current state-of-the-art AQUA® method for quantitating prote...
Mar 29, 2017
SEATTLE, March 29, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, is releasing multiple new products at the American Association of Cancer Research (AACR) Meeting. The new products build on NanoString's existing portfolio of produ...
Mar 27, 2017
SEATTLE, March 27, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the upcoming presentation of recent research in precision oncology and predictive biomarkers using the nCounter® Analysis System. More than 45 ...
Mar 23, 2017
SEATTLE, March 23, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of nCounter® PlexSet™ reagents at the Association of Biomolecular Resource Facilities (ABRF) conference in San Dieg...
Mar 1, 2017
SEATTLE, March 01, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2016. Fourth Quarter Financial Highlights Total revenue of $25.2 million, ...
Feb 27, 2017
ORLANDO, Fla., Feb. 27, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted a novel approach to profiling immuno-oncology protein targets through digital quantification using the nCounter® Analysis System. The da...
Feb 24, 2017
SEATTLE, Feb. 24, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2016 financial results after the close of trading on Wednesday, March 1, 2017. Company m...
Feb 22, 2017
SEATTLE, Feb. 22, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston. Brad Gray, presid...
Feb 16, 2017
Hyb & Seq Single Molecule Chemistry Sequences Oncogenes from FFPE Samples with High Accuracy and Simple Workflow Free of Library, Enzymes and Amplification 3D Biology Enables Simultaneous Detection of Somatic DNA Mutations and Expressed Fusion Transcripts plus Expression Profiling of Proteins from Lung-Tumor FFPE Samples Digital Spatial Profi...
Jan 31, 2017
SEATTLE, Jan. 31, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Humana has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature Assay. Humana and its more than 13 million me...
Jan 10, 2017
SEATTLE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Blue Cross Blue Shield Association Evidence Street has issued a positive assessment of the Prosigna® Breast Cancer Gene Signature Assay...
Jan 10, 2017
- Expected Full Year 2016 Revenue Growth of 36% to 39% Year over Year - SEATTLE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended Decemb...
Dec 22, 2016
SEATTLE, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the J.P. Morgan 35th Annual Healthcare Conference in San Francisco. Brad Gray, presid...
Dec 12, 2016
Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Negative Patients Over a 10-Year Period SEATTLE, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic produ...
Dec 5, 2016
SEATTLE, Dec. 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced advances in precision oncology using the Prosigna® Breast Cancer Gene Signature Assay and the PAM50 gene signature, the basis for Prosigna, will...
Dec 1, 2016
SEATTLE, Dec. 01, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its nCounter Vantage 3D™ assays, a portfolio of panels that enable simultaneous analysis of DNA, RNA, and protein were listed by The Scien...
Nov 30, 2016
SEATTLE, Nov. 30, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and hematology using the nCounter® platform that will be presented at the Annual Meeti...
Nov 11, 2016
In Special Recognition of the work of The Stand Up To Cancer-Lustgarten Foundation Pancreatic Dream Team and in honor of Pancreatic Cancer Awareness Month SEATTLE, Nov. 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today...
Nov 7, 2016
SEATTLE, Nov. 07, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, has begun accepting applications to a Technology Access Program (TAP) for its novel Digital Spatial Profiling technology (formerly referred to as digital IHC). In co...
Nov 2, 2016
SEATTLE, Nov. 02, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter ended September 30, 2016. Third Quarter Financial Highlights Total revenue of $23.9 million, 53% year-ov...
Oct 19, 2016
VANCOUVER, British Columbia, Oct. 19, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an update on the company's Hyb & Seq™ platform which is currently in development. Hyb & Seq is a library-free, amplificatio...
Oct 18, 2016
SEATTLE, Oct. 18, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of two new translational research assays in the company's Vantage 3D product line at the American Society of Human Genetics (AS...
Oct 5, 2016
SEATTLE, Oct. 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2016 financial results after the close of trading on Wednesday, November 2, 2016. Company management will...
Sep 13, 2016
SEATTLE, Sept. 13, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Kirk Malloy, Ph.D. to the company's Board of Directors, effective September 12, 2016.  The Board now consists of seven members.  ...
Aug 25, 2016
SEATTLE, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at two upcoming conferences in September. Presenting at the conferences will be Brad Gray, Chie...
Aug 3, 2016
Revenue Growth of 73% Year-Over-Year Driven by Strong nCounter SPRINT Demand, Robust Consumable Pull-Through and Achievement of Biopharma Collaboration Milestones SEATTLE, Aug. 03, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic product...
Jul 7, 2016
SEATTLE, July 07, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release second quarter 2016 financial results after the close of trading on Wednesday, August 3, 2016. Company management will ...
Jun 2, 2016
SEATTLE, June 02, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and immunotherapy using the nCounter® platform that will be presented at the Annual Me...
May 26, 2016
SEATTLE, May 26, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna® Breast Cancer Gene Signature Assay.  Cigna and its ro...
May 24, 2016
SEATTLE, May 24, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Jefferies 2016 Healthcare Conference in New York, NY. Brad Gray, President and Chief...
May 9, 2016
SEATTLE, May 09, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Aetna has added the Prosigna® Breast Cancer Gene Signature Assay to its Tumor Markers Clinical Policy Bulletin.  Aetna and its more ...
May 5, 2016
SEATTLE, May 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter ended March 31, 2016. First Quarter Financial Highlights Total revenue of $14.7 million, 27% year-over-y...
Apr 27, 2016
SEATTLE, April 27, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV. Brad G...
Apr 18, 2016
NEW ORLEANS, April 18, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today presented the first proof-of-concept data from its novel multiplexed digital immunohistochemistry (IHC) technology at the American Association for Cancer ...
Apr 14, 2016
nCounter Vantage Products Enable Simultaneous Analysis of DNA, RNA, and Protein to Expand Capabilities In Cancer Research, Including Immuno-Oncology Multiple New Products to be Featured at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans SEATTLE, April 14, 2016 (GLOBE NEWSWIRE) -- NanoString Technologi...
Apr 13, 2016
SEATTLE, April 13, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2016 financial results after the close of trading on Thursday, May 5, 2016. Company management will host...
Apr 11, 2016
SEATTLE and MARSEILLE, France, April 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and HalioDx SAS, a diagnostic company in immuno-oncology, today announced they have entered into an agreement to jointly develop and commercia...
Mar 21, 2016
SEATTLE, March 21, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Noridian Healthcare Solutions, LLC, a Medicare Administrative Contractor (MAC) for two Medicare jurisdictions covering 13 states, has issued fa...
Mar 10, 2016
SEATTLE and DANVERS, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and Cell Signaling Technology (CST), a worldwide provider of antibodies, have reached an agreement to use highly validated antibodies from CST in...
Feb 29, 2016
SEATTLE, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2015. Fourth Quarter Financial HighlightsTotal revenue of $22.3 million, 43% y...
Feb 29, 2016
SEATTLE, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the US and Canada, through a subsidiary, to develop and commercia...
Feb 22, 2016
SEATTLE, Feb. 22, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston. Brad Gray, Presiden...
Feb 12, 2016
SEATTLE, Feb. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release fourth quarter 2015 financial results after the close of trading on Monday, February 29, 2016. Company management will ...
Feb 11, 2016
ORLANDO, Fla., Feb. 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today presented the first proof-of-concept data for its novel massively parallel single molecule sequencing chemistry, Hyb & SeqTM, at the Advances in Genome B...
Feb 9, 2016
SEATTLE, Feb. 09, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the updated American Society of Clinical Oncology (ASCO) Clinical Practice Guideline on the appropriate use of breast tumor biomarker assay resu...
Jan 27, 2016
SEATTLE, Jan. 27, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City. Brad Gra...
Jan 10, 2016
SEATTLE, Jan. 10, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended December 31, 2015. Financial Highlights: Total revenue for 2015 expected to be ...
Jan 7, 2016
SAN FRANCISCO, CA and SEATTLE, WA--(Marketwired - Jan 7, 2016) - Medivation, Inc. (NASDAQ: MDVN) and NanoString Technologies, Inc., (NASDAQ: NSTG) today announced they have entered into a collaboration, together with Astellas Pharma Inc., to pursue the translation of a novel gen...
Dec 23, 2015
SEATTLE, Dec. 23, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco. Brad Gray, Presid...
Dec 7, 2015
SEATTLE, Dec. 7, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that eleven posters for the Prosigna® Breast Cancer Gene Signature Assay and the PAM50 gene signature, the basis for Prosigna, will be presented at...
Nov 5, 2015
SEATTLE, Nov. 5, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City. Brad G...
Nov 5, 2015
SEATTLE, Nov. 5, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels e...
Nov 2, 2015
Record Revenue of $15.7 Million Driven by Strong Consumables Demand Expanded Solutions in Precision Oncology, including nCounter SPRINT and 3D Biology, Strengthen Company's Position at Center of Cancer Ecosystem SEATTLE, Nov. 2, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools f...
Oct 12, 2015
SEATTLE, Oct. 12, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release third quarter 2015 financial results after the close of trading on Monday, November 2, 2015. Company management will host...
Sep 11, 2015
NEW YORK, Sept. 11, 2015 (GLOBE NEWSWIRE) -- At a meeting with analysts and investors today, members of the senior management team of NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, plan to unveil the company's strategic roadmap to drive continued growth and...
Sep 10, 2015
SEATTLE, Sept. 10, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of the nCounter® RNA:Protein PanCancer Immune Profiling Panel. The panel can be analyzed on the full line of nCounter Analy...
Sep 9, 2015
SEATTLE, Sept. 9, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the PAM50 gene signature, commercialized as the Prosigna® Breast Cancer Gene Signature Assay, has been added to the European Society for Medi...
Aug 27, 2015
SEATTLE, Aug. 27, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will host a meeting for analysts and institutional investors on Friday, September 11, 2015, in New York City from 8:00 a.m. to approximately 10...
Aug 26, 2015
SEATTLE, Aug. 26, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Brad Gray, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: The 2015 Baird Healt...
Aug 13, 2015
SEATTLE, Aug. 13, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies through its MolDx program, has issued a f...
Aug 4, 2015
Cancer Focus and Leadership in Immuno-Oncology Strengthened by Collaboration with Merck Launch of nCounter SPRINT Broadens Reach in Cancer Research Market SEATTLE, Aug. 4, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic produc...
Jul 30, 2015
SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Canaccord Genuity Growth Conference in Boston. Brad Gray, President and Chief Executive Offi...
Jul 21, 2015
SEATTLE, July 21, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release second quarter 2015 financial results after the close of trading on Tuesday, August 4, 2015. Company management will host...
Jul 16, 2015
SEATTLE, July 16, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for breast cancer have been updated to acknowledge that ...
Jul 15, 2015
Expanded nCounter® Instrument Product Line Expected to Reach Deeper Into Cancer Research Market SEATTLE, July 15, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of the nCounter Analysis Sys...
Jul 8, 2015
SEATTLE, July 8, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Alessandra Cesano, M.D., Ph.D. has been named Chief Medical Officer, effective July 6, 2015. Dr. Cesano brings more than 25 years of experi...
Jul 7, 2015
SEATTLE, July 7, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a study online in Clinical Cancer Research that reinforces the ability of the company's Prosigna® Breast Cancer Assay to inform ...
Jun 1, 2015
Prosigna Shown to Predict Response to Chemotherapy Prognostic Accuracy Confirmed in Comprehensive Nationwide Population Study Second Decision Impact Study Confirms Prosigna Changes Physician Treatment Decisions SEATTLE, June 1, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (Nasdaq:NSTG) a provider of life scien...
May 28, 2015
Collaboration Builds on Merck's R&D and NanoString's Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWO...
May 14, 2015
SEATTLE, May 14, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies through its MolDx program, has issued a fa...
May 12, 2015
SEATTLE, May 12, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (Nasdaq:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the PAM50 gene signature, commercialized as the Prosigna® Breast Cancer Prognostic Gene Signature Assay, was included for the first time in th...
May 7, 2015
SEATTLE, May 7, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the UBS Global Healthcare Conference in New York. Brad Gray, President and Chief Executive Officer...
May 6, 2015
Strong Q1 2015 Revenue Growth of 32% Year over Year Cancer Focus Intensified With Recent Cancer Immunotherapy Trials Network and MD Anderson Collaborations and Innovative New Products Including Expanded Offerings in Immuno-Oncology SEATTLE, May 6, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of li...
May 5, 2015
SEATTLE, May 5, 2015 (GLOBE NEWSWIRE) -- The Cancer Immunotherapy Trials Network (CITN) and NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year translational research collaboration to discover biomarkers that predict clinical outcome...
Apr 22, 2015
SEATTLE, April 22, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2015 financial results after the close of trading on Wednesday, May 6, 2015. Company management will host ...
Apr 16, 2015
Introduction of RNA:Protein Profiling Panel Focused on Immuno-Oncology Addresses the Next Generation of Tumor Profiling Launch of Two New PanCancer Gene Expression Panels Strengthens Portfolio of Tools to Thoroughly Analyze the Hallmarks of Cancer and Expands Offerings in Immuno-Oncology SEATTLE, April 16, 2015 (GLOBE NEWSWIRE) -- N...
Apr 1, 2015
HOUSTON and SEATTLE, April 1, 2015 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a revolution...
Mar 18, 2015
SEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its Prosigna® Breast Cancer Assay is now acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (A...
Mar 3, 2015
SEATTLE, March 3, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Robert Hershberg, M.D., Ph.D. has been appointed to its Board of Directors, effective March 2, 2015. The Board now consists of six members. ...
Feb 24, 2015
SEATTLE, Feb. 24, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2014. Fourth Quarter Financial Highlights: Total revenue of $...
Feb 18, 2015
SEATTLE, Feb. 18, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Cowen and Company 35th Annual Health Care Conference in Boston. Brad Gray, President and Chi...
Feb 10, 2015
SEATTLE, Feb. 10, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter 2014 financial results after the close of trading on Tuesday, February 24, 2015. Company management will h...
Jan 28, 2015
SEATTLE, Jan. 28, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York. Brad Gray, President and Chief Execut...
Jan 8, 2015
- Expected Full Year 2014 Revenue Growth of 50% to 53% Year over Year - SEATTLE, Jan. 8, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided an update on operational and preliminary financial results for the year e...
Dec 22, 2014
SEATTLE, Dec. 22, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its management is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco. Brad Gray, President and Chi...
Dec 15, 2014
Study Shows that Prosigna Influences Whether Oncologists Recommend Chemotherapy in Real-World Setting SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announce...
Dec 8, 2014
The Prosigna Score Provides Important Information for Node-Negative and Node-Positive (1-3 Nodes) Breast Cancer Patients in the First 5 Years and 5 to 10 Years After Diagnosis SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools fo...
Dec 1, 2014
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that multiple posters for the Prosigna® Breast Cancer Gene Signature Assay based on PAM50 will be presented at the 37...
Nov 7, 2014
SEATTLE, Nov. 7, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City. Brad Gray, President and C...
Nov 4, 2014
SEATTLE, Nov. 4, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter ended September 30, 2014. Financial Highlights: Record total revenue of $12.3 million, 47% ...
Oct 21, 2014
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the Journal of Clinical Oncology published an analysis of data in over 2,100 patients showing that the risk-of-recurr...
Oct 9, 2014
SEATTLE, Oct. 9, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2014 financial results after the close of trading on Tuesday, November 4, 2014. Company management will host...
Oct 6, 2014
BOSTON & SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's ...
Sep 9, 2014
PanCancer Immune Profiling Panel Enables Researchers to Develop Profiles of the Human Immune Response in all Cancer Types SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, ...
Aug 27, 2014
SEATTLE, Aug. 27, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., (Nasdaq:NSTG) a provider of life science tools for translational research, and molecular diagnostic products, today announced the unexpected death of J. Wayne Cowens, M.D., the company's Chief Medical Officer. Dr. Cowens was 67 years old. "We are shocked and deeply sa...
Aug 21, 2014
SEATTLE, Aug. 21, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science translational research and molecular diagnostic products, today announced that Brad Gray, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: The 2014 Baird Healthcare Conf...
Aug 5, 2014
The Prosigna Assay is the First Genomic Breast Cancer Diagnostic Test Approved in Australia to Assess a Woman's 10-year Risk of Distant Recurrence SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and ...
Aug 5, 2014
- Strong Q2 2014 Revenue Growth of 51% Year over Year - - Initiation of First Companion Diagnostic Collaboration with Celgene Corporation - SEATTLE, Aug. 5, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported ...
Jul 29, 2014
Assay Design Technology Licensed from Harvard University Expands Utility of nCounter Elements SEATTLE & CHICAGO--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announ...
Jul 21, 2014
SEATTLE, July 21, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2014 second quarter financial results after the close of trading on Tuesday, August 5, 2014. Company management will host...
Jun 11, 2014
SEATTLE, June 11, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the JMP Securities Healthcare Conference 2014 in New York. NanoString management is scheduled to present on Wednesday, June 25, 2014 at 9:00 am ET. Interested parties can access the live ...
Jun 3, 2014
NanoString Eligible to Receive up to $45 million for Upfront, Developmental and Regulatory Milestones, and Commercial Payments from Celgene SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecul...
May 19, 2014
SEATTLE, May 19, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Jefferies 2014 Global Healthcare Conference in New York. NanoString management is scheduled to present on Wednesday, June 4, 2014 at 4:00 pm ET. Interested parties can access the live ...
May 7, 2014
- Strong Q1 2014 Revenue Growth of 54% Year over Year - - Q1 2014 Instrument Revenue of $3.4 Million, Up 110% Year over Year - SEATTLE, May 7, 2014 (GLOBE NEWSWIRE) --NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial result...
May 6, 2014
The Prosigna Assay on the nCounter Dx Analysis System Provides Compelling Clinical Data, Clear Patient Report, and Localized Processing in Qualified Canadian Labs SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translation...
May 1, 2014
SEATTLE, May 1, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Bank of America Merrill Lynch Healthcare Conference in Las Vegas. NanoString management is scheduled to present on Wednesday, May 14, 2014 at 4:00 pm ET. Interested parties can access t...
Apr 30, 2014
SEATTLE, April 30, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of veteran diagnostics executive Tina S. Nova, Ph.D. to its Board of Directors. Dr. Nova will also join the Board's Compensation Commi...
Apr 16, 2014
SEATTLE, April 16, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2014 first quarter financial results after the close of trading on Wednesday, May 7, 2014. Company management will host ...
Apr 7, 2014
nCounter PanCancer Pathways Panel Streamlines the Study of All Major Cancer Pathways and Associated Driver Genes SEATTLE & SAN DIEGO--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagn...
Apr 3, 2014
SEATTLE, April 3, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a term loan agreement with Capital Royalty L.P. and certain of its affiliates. The agreement provides NanoString with up to $4...
Mar 13, 2014
Successful Validation on the nCounter Dx Analysis System Supports ‘Decentralized' Use of the Prosigna Assay in Clinical Laboratories SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnos...
Feb 26, 2014
- Strong Q4 2013 Revenue Growth of 56% Year over Year - - Record Q4 2013 Instrument Revenue of $5.3 Million, Up 109% Year over Year - - Full Year Total Revenue of $31.4 Million, Up 37% Year over Year - SEATTLE, Feb. 26, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for tran...
Feb 19, 2014
SEATTLE, Feb. 19, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston. NanoString management is scheduled to present on Wednesday, March 5, 2014 at 11:20 am ET. Interested parties can access the live au...
Feb 12, 2014
Authors Conclude that the PAM50-based Prosigna Assay can Predict Risk of Late Distant Recurrence Between Years Five and 15 after Diagnosis SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnos...
Feb 11, 2014
nCounter® Elements™ General Purpose Reagents Expand the Company's Growing Portfolio of Solutions for Laboratories to Develop Tests for Personalized Medicine SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science ...
Feb 5, 2014
SEATTLE, Feb. 5, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 fourth quarter financial results after the close of trading on Wednesday, February 26, 2014. Company management will ...
Jan 29, 2014
SEATTLE, Jan. 29, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that its management is scheduled to participate in the Leerink Swann Global Healthcare Conference 2014 in New York. NanoString management is scheduled to present on Wednesday, February 12, 2014 at 3:05 pm ET. Interested parties can access...
Jan 23, 2014
SEATTLE, Jan. 23, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its follow-on public offering of $55 million of its common stock at a price to the public of $18.50 per share. In addition, the Company has granted th...
Jan 21, 2014
SEATTLE, Jan. 21, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of a proposed follow-on public offering of $55 million of its common stock. In addition, the Company expects to grant the underwriters a 30-day option to ...
Jan 15, 2014
SEATTLE, Jan. 15, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an exclusive option from Massachusetts General Hospital to license intellectual property related to a novel approach for multiplexe...
Jan 13, 2014
SEATTLE, Jan. 13, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of $55 million of its common sto...
Jan 13, 2014
Approximately 55% fourth quarter and 37% full year 2013 year-over-year revenue growth anticipated Record fourth quarter instrument revenue of approximately $5.3 million, up 112% year-over-year SEATTLE, Jan. 13, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational re...
Jan 6, 2014
SEATTLE, Jan. 6, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) today announced that its management is scheduled to participate in the JP Morgan 32nd Annual Healthcare Conference on January 15, 2014 in San Francisco. NanoString management is scheduled to present at 4:00pm PT/ 7:00 pm ET. Interested parties can access t...
Dec 18, 2013
Authors Conclude that the PAM50 Based Prosigna Assay has Achieved Level 1 Evidence, Supporting Potential Inclusion in Future Cancer Treatment Guidelines SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational resear...
Dec 13, 2013
Prosigna Combined Analysis of TransATAC and ABCGS-8 Data Presented at the 2013 San Antonio Breast Cancer Symposium SEATTLE & SAN ANTONIO--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic produc...
Dec 10, 2013
Premier Diagnostic Labs ARUP Laboratories, LabCorp, and Quest Diagnostics to Offer the Prosigna Breast Cancer Assay Conference Call to Discuss Details; Tomorrow at 8:30AM EST SEATTLE & SAN ANTONIO--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of l...
Nov 20, 2013
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of David W. Ghesquiere as Senior Vice President, Corporate & Business Development, effective immediately. ...
Nov 18, 2013
SEATTLE, Nov. 18, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) today announced that its management is scheduled to participate in the Piper Jaffray 25th Annual Healthcare Conference on December 3, 2013 in New York. NanoString management is scheduled to present at 4:30 pm ET. Interested parties can access the live aud...
Nov 12, 2013
Multi-Mode System Available for Running the Prosigna Breast Cancer Assay,Other Multiplexed Research Assays, and Laboratory Developed Tests SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecul...
Nov 5, 2013
- Strong Q3 2013 Revenue Growth of 39% - - Record Instrument Revenue of $3.6 Million, Up 63% - SEATTLE, Nov. 5, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the three and nine ...
Oct 29, 2013
SEATTLE, Oct. 29, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), announced today that its management is scheduled to present at the Credit Suisse 2013 Healthcare Conference in Phoenix on Tuesday, November 12, 2013 at 8:30 am MT/ 10:30 am ET. Interested parties can access the live audio webcast for the conference at ww...
Oct 16, 2013
SEATTLE, Oct. 16, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 third quarter financial results after the close of trading on Tuesday, November 5, 2013. Company management will hos...
Oct 1, 2013
SEATTLE, Oct. 1, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) and Fluidigm Corporation (Nasdaq:FLDM) have agreed to settle lawsuits filed by Fluidigm in the United States and Singapore. In the U.S. case, Fluidigm charged NanoString with false advertising, unfair competition, and unlawful trade practices based on a comparison...
Sep 16, 2013
Authors concluded that PAM50 Gene Signature was better than Oncotype DX® and IHC4 Assays at Categorizing Patients into Low and High Risk for Late Distant Recurrence SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science ...
Sep 9, 2013
Prosigna Assay on the nCounter® Dx Analysis System Provides Compelling Clinical Data,Clear Patient Report, and Decentralized Testing in Qualified Labs SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for tr...
Sep 5, 2013
SEATTLE and SAN JOSE, Calif., Sept. 5, 2013 /PRNewswire/ -- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, and BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a colla...
Aug 26, 2013
SEATTLE, Aug. 26, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), today announced that it will be participating in two upcoming investor conferences. NanoString Technologies management is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference in New York on Monday, September 9, 2013 at 11:45 a...
Aug 6, 2013
SEATTLE, Aug. 6, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the three and six months ended June 30, 2013. Highlights of the second quarter include: Total revenue of $7.2...
Jul 29, 2013
nCounter Elements General Purpose Reagents are First NanoString Product with Open Architecture to Support Independent Development of Diagnostic Tests SEATTLE & HOUSTON--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational...
Jul 17, 2013
SEATTLE, July 17, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release 2013 second quarter financial results after the close of trading on Tuesday, August 6, 2013. Company management will host...
Jul 2, 2013
Authors Conclude that PAM50-based Assay Provides More Prognostic Information than Oncotype DX ® with Better Differentiation of Intermediate and High Risk Groups SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for transla...
Jun 25, 2013
SEATTLE--(BUSINESS WIRE)--June 25, 2013-- NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of its initial public offering of 5.4 million shares of common stock at a price to the public of $10.00 per share. In addition, the Company has granted th...
Jun 3, 2013
SEATTLE and CHICAGO | June 3, 2013 — NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Com...
May 20, 2013
SEATTLE | May 20, 2013 – NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed ...
May 15, 2013
SEATTLE and CHICAGO | May 15, 2013 — NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today a...
May 2, 2013
Positive Results from Two Studies of the PAM50-Based In Vitro Diagnostic Assay will be Presented at the Annual IMPAKT Breast Cancer Conference SEATTLE and BRUSSELS, BELGIUM | May 2, 2013 ...
Apr 17, 2013
SEATTLE, Wash. | April 17, 2013 – NanoString® Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, toda...
Mar 6, 2013
PAM50-based In Vitro Diagnostic Run in Multiple Qualified Laboratories on the nCounter® System Demonstrated High Precision and Reproducibility SEATTLE and BALTIMORE, Md. | ...
Feb 28, 2013
Added Experience in Quality, Regulatory and Legal Supports Diagnostics Business SEATTLE | February 28, 2013 – NanoString Technologies, Inc., a privately held provider o...
Dec 6, 2012
Study Demonstrates Ability of PAM50 Assay to Indicate Risk of Recurrence in Women with HR+ Early-Stage Breast Cancer Treated with Endocrine Therapy AloneSEATTLE, Wash. and San Antonio, TX | December 6, 2012 ...
Dec 3, 2012
SEATTLE, Wash. | December 3, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic produ...
Dec 3, 2012
SEATTLE, Wash., and San Antonio, TX | December 3, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molec...
Oct 3, 2012
Industry Veteran Brings More Than 20 Years of Life Sciences Financial ExpertiseSEATTLE, Wash. | October 3, 2012 – NanoString Technologies, Inc., a privately-held provider...
Sep 27, 2012
Testing Kit Available in Early 2013 Will Offer EU Patients Risk of Recurrence Score and Intrinsic SubtypingSEATTLE, Wash | September 27, 2012 – NanoString Technologies, I...
Sep 24, 2012
Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor BiologySEATTLE, Wash. | September 24, 2012 – On September 23, researchers publish...
Sep 23, 2012
Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor BiologySEATTLE, Wash. | September 24, 2012 – On September 23, researchers publish...
Aug 7, 2012
SEATTLE, Wash. | August 7, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, ...
Jul 18, 2012
Seattle, WA | July 18, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today ann...
May 29, 2012
SEATTLE, Wash. | May 29, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today a...
May 16, 2012
Study to Evaluate the Ability of PAM50 to Estimate Prognosis in Women with Early-Stage Breast CancerSEATTLE, Wash. | May 16, 2012 – NanoString Technologies, Inc., a priva...
Apr 9, 2012
SEATTLE, Wash. | April 9, 2012   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics,...
Apr 3, 2012
Alexandria, VA | April 3, 2012   -  Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies,...
Mar 30, 2012
New Offerings Accelerate the Completion of Studies and Expand FFPE Analysis Portfolio SEATTLE, Wash. | March 30, 2012 ...
Dec 8, 2011
Study Establishes Prognostic Performance of NanoString's First Diagnostic Product, Demonstrates NanoString's Assay Provides Significantly More Prognostic Information and Assigns Fewer Patients to Intermediate Risk Group than Genomic Health's Oncotype DX® ...
Nov 7, 2011
New Investors include GE healthymagination Fund, BioMed Ventures and Henri Termeer SEATTLE | November 7, 2011 ...
Oct 12, 2011
New Features Support Larger Translational Research Studies and Development of nCounter-based Diagnostics SEATTLE, Wash. and MONTREAL, Canada | October 12, 2011...
Sep 21, 2011
Kit Enables Profiling of Up To 30 miRNAs and 200 mRNAs in a Single Tube without Amplification SEATTLE, Wash | September 21, 2011 ...
Aug 5, 2011
Kit Enables Profiling of More than 400 Rat miRNAs in a Single Tube without Amplification SEATTLE, Wash | August 5, 2011 ...
Aug 3, 2011
Study to Evaluate Disease Prognosis Using NanoString? PAM50-based Assay on the TransATAC Sample Set SEATTLE, Wash | August 3, 2011 ...
Jul 28, 2011
Multiplexed Assay Kit Provides Simple, Cost-effective Solution to Characterize Samples for Researchers SEATTLE, Wash | July 28, 2011 ...
Jun 3, 2011
NanoString Technologies Developing Distributed Assay Platform for Potential Use in Clinical Diagnostics SEATTLE, Wash., and CHICAGO, Ill | June 3, 2011 ...
Feb 22, 2011
Panel Provides Cost Effective Way to Monitor Cell Line Quality, Perform Cytogenetics Research SEATTLE, Wash | February 22, 2011 ...
Feb 1, 2011
Veteran industry clinical oncologist to help build company's diagnostics pipeline SEATTLE, Wash | February 1, 2011 ...
Jan 25, 2011
SEATTLE, Wash | January 25, 2011   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of ta...
Dec 6, 2010
Company Intends to Commercialize In Vitro Diagnostic Products on its nCounter Platform SEATTLE, Wash | December 6, 2010 ...
Nov 2, 2010
WASHINGTON, D.C | November 2, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of ...
Oct 6, 2010
SEATTLE, Wash | October 6, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of tar...
Jul 14, 2010
Researchers can now directly profile up to 800 transcripts in a single tube SEATTLE, Wash | July 14, 2010 ...
Jun 29, 2010
Brad Gray Joins as President and Chief Executive Officer, and Nalini Murdter Named Chief Business Officer SEATTLE, Wash | June 29, 2010 ...
Jun 10, 2010
Custom Copy Number Variation Assays Provide a Simple and Precise Way to Detect Hundreds of Variants in a Single Multiplexed Reaction GOTHENBURG, Sweden and SEATTLE, Wash | ...
May 6, 2010
nCounter Analysis System Poised for Development as a Diagnostics Platform SEATTLE, Wash | May 6, 2010 ...
Apr 19, 2010
SEATTLE, Wash | April 19, 2010 NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molec...
Feb 3, 2010
SEATTLE, Wash | February 3, 2010   -  NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large set...
Nov 18, 2009
SEATTLE, Wash | November 18, 2009   -  NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced...
Oct 22, 2009
SEATTLE, Wash | October 22, 2009   -  NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced ...
Jun 9, 2009
Clarus Ventures Leads Financing SEATTLE, Wash | June 9, 2009   ...
Page:
...
Next Last
 
= add file to Briefcase